Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0302486 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Regina Munter-Young und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Market Access, GE HealthCare, Marlborough, MA, United States of America. Hauptthemen laut MEDLINE: Breast Neoplasms, Cost-Benefit Analysis, Positron Emission Tomography Computed Tomography, Receptors, Estrogen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GE Healthcare.
Abstract (Originalsprache)
Background and objectives Correct identification of estrogen receptor (ER) status in breast cancer (BC) is crucial to optimize treatment; however, standard of care, involving biopsy and immunohistochemistry (IHC), and other diagnostic tools such as 2-deoxy-2-[ 18 F]fluoro-D-glucose or 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG), can yield inconclusive results. 16α-[ 18 F]fluoro-17β-fluoroestradiol ([ 18 F]FES) can be a powerful tool, providing high diagnostic accuracy of ER-positive disease. The aim of this study was to estimate the budget impact and cost-effectiveness of adding [ 18 F]FES PET/CT to biopsy/IHC in the determination of ER-positive status in metastatic (mBC) and recurrent breast cancer (rBC) in the United States (US).
Methods
An Excel-based decision tree, combined with a Markov model, was developed to estimate the economic consequences of adding [ 18 F]FES PET/CT to biopsy/IHC for determining ER-positive status in mBC and rBC over 5 years. Scenario A, where the determination of ER-positive status is carried out solely through biopsy/IHC, was compared to scenario B, where [ 18 F]FES PET/CT is used in addition to biopsy/IHC.
Results
The proportion of true positive and true negative test results increased by 0.2 to 8.0 percent points in scenario B compared to scenario A, while re-biopsies were reduced by 94% to 100%. Scenario B resulted in cost savings up to 142 million dollars.
Conclusions
Adding [ 18 F]FES PET/CT to biopsy/IHC may increase the diagnostic accuracy of the ER status, especially when a tumor sample cannot be obtained, or the risk of a biopsy-related complication is high. Therefore, adding [ 18 F]FES PET/CT to biopsy/IHC would have a positive impact on US clinical and economic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Market Access, GE HealthCare, Marlborough, MA, United States of America.
- Global Medical Affairs, GE HealthCare, Marlborough, MA, United States of America.
- Medical Affairs, GE HealthCare, Marlborough, MA, United States of America.
- Certara Germany GmbH, Evidence and Access, Loerrach, Germany.
ORCID-Profile: Regina Munter-Young
Förderung
- GE Healthcare
Zitieren
APA
Munter-Young, R., Fuentes-Alburo, A., DiGregorio, N., Neeser, K., & Gultyaev, D. (2024). Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US. PLOS ONE. https://doi.org/10.1371/journal.pone.0302486
Vancouver
Munter-Young R, Fuentes-Alburo A, DiGregorio N, Neeser K, Gultyaev D. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US. PLOS ONE. 2024. doi:10.1371/journal.pone.0302486
BibTeX
@article{MunterYoung2024,
author = {Munter-Young, Regina and Fuentes-Alburo, Adolfo and DiGregorio, Nicholas and Neeser, Kurt and Gultyaev, Dmitry},
title = {Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0302486}
}
EUVIMED